Effect of vitamin D supplementation on type 2 diabetic patients with hypertension.

Phase 3

Completed

• Conditions: Condition 1: Diabetes. Condition 2: Hypertension.; Type 2 diabetes mellitus; Essential (primary) hypertension

• Registration Number: IRCT20191223045861N1
• Lead Sponsor: Oroumia University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 2020-02-24

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 46

Inclusion Criteria

At least 5 years diabetes history based on self-reported
Diabetes control with metformin, Glibenclamide, glitazone, Gliclazide or a combination of these
Blood pressure control with any of the Angiotensin receptor blockers (ARB), ACE Inhibitor, Calcium channel blockers (CCB), Thiazide diuretics or a combination of these

Exclusion Criteria

Pregnancy and lactation
Gastrointestinal diseases such as malabsorption
History of cardiovascular problems
Kidney? liver and other endocrine diseases
Malignancy
Type 1 diabetes
BMI<40
The consumption of vitamin D and multivitamin mineral supplements over the past 3 months
Drugs affecting vitamin D and calcium metabolism,
Insulin therapy
Weight loss medications such as Orlistat

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Flow-mediated dilatation changes. Timepoint: At baseline and week12. Method of measurement: Ultrasonography.;ICAM1. Timepoint: At baseline and week 12. Method of measurement: Serum level measurement using ELISA kit.;Oxidized LDL. Timepoint: At baseline and week 12. Method of measurement: Serum level measurement using ELISA kit.